Advertisement
Advertisement
January 20, 2013
PEARL Registry's Phase II Results Presented at ISET
January 21, 2013—Results of the multicenter PEARL II registry suggest that rheolytic pharmacomechanical thrombectomy using combination therapy is a fast and effective method for treating deep vein thrombosis (DVT), reducing treatment time from more than 2 days to less than 24 hours. The PEARL registry is studying the AngioJet thrombectomy device (Bayer Radiology and Interventional, Indianola, PA). Phase II data were presented at the 25th annual International Symposium on Endovascular Therapy (ISET) in Miami Beach, Florida.
The PEARL II study was composed of 371 DVT patients who were treated at 35 centers, with 38% of treatments completed in < 6 hours and 76% in < 24 hours. After 12 months, 80% of patients remained free of DVT. Stents were placed in 116 patients (most in the pelvic arteries) to correct obstructions and prevent future clot formation.
“We're on the verge of a truly outpatient procedure for the treatment of DVT,” commented study director Robert Lookstein, MD, in the ISET press release. Dr. Lookstein is Chief of Interventional Radiology at Mount Sinai Medical Center in New York City. “This is a transformative technology that will enable more people who are suffering from DVT to have fast, effective, minimally invasive therapy.”
Advertisement
Advertisement
